410 related articles for article (PubMed ID: 15050647)
1. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
2. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
3. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
Capuron L; Ravaud A; Neveu PJ; Miller AH; Maes M; Dantzer R
Mol Psychiatry; 2002; 7(5):468-73. PubMed ID: 12082564
[TBL] [Abstract][Full Text] [Related]
4. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
Capuron L; Ravaud A; Dantzer R
J Clin Oncol; 2000 May; 18(10):2143-51. PubMed ID: 10811680
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
Wichers MC; Kenis G; Koek GH; Robaeys G; Nicolson NA; Maes M
J Psychosom Res; 2007 Feb; 62(2):207-14. PubMed ID: 17270579
[TBL] [Abstract][Full Text] [Related]
6. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
7. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
Capuron L; Ravaud A; Gualde N; Bosmans E; Dantzer R; Maes M; Neveu PJ
Psychoneuroendocrinology; 2001 Nov; 26(8):797-808. PubMed ID: 11585680
[TBL] [Abstract][Full Text] [Related]
8. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
[TBL] [Abstract][Full Text] [Related]
9. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
10. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment.
Devine D; Parker PA; Fouladi RT; Cohen L
Psychooncology; 2003; 12(5):453-62. PubMed ID: 12833558
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
12. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
Pizzi C; Caraglia M; Cianciulli M; Fabbrocini A; Libroia A; Matano E; Contegiacomo A; Del Prete S; Abbruzzese A; Martignetti A; Tagliaferri P; Bianco AR
Anticancer Res; 2002; 22(2A):727-32. PubMed ID: 12014643
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
Raison CL; Woolwine BJ; Demetrashvili MF; Borisov AS; Weinreib R; Staab JP; Zajecka JM; Bruno CJ; Henderson MA; Reinus JF; Evans DL; Asnis GM; Miller AH
Aliment Pharmacol Ther; 2007 May; 25(10):1163-74. PubMed ID: 17451562
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.
Laguno M; Blanch J; Murillas J; Blanco JL; León A; Lonca M; Larrousse M; Biglia A; Martinez E; García F; Miró JM; de Pablo J; Gatell JM; Mallolas J
Antivir Ther; 2004 Dec; 9(6):905-9. PubMed ID: 15651749
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
18. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.
Albrecht K; Droll H; Giesler JM; Nashan D; Meiss F; Reuter K
Psychooncology; 2013 Sep; 22(9):1972-8. PubMed ID: 23288588
[TBL] [Abstract][Full Text] [Related]
19. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
20. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
